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Genome-wide association analyses identify 143
risk variants and putative regulatory mechanisms
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Type 2 diabetes (T2D) is a very common disease in humans. Here we conduct a meta-
analysis of genome-wide association studies (GWAS) with ~16 million genetic variants in
62,892 T2D cases and 596,424 controls of European ancestry. We identify 139 common
and 4 rare variants associated with T2D, 42 of which (39 common and 3 rare variants)
are independent of the known variants. Integration of the gene expression data from blood
(n= 14,115 and 2765) with the GWAS results identiﬁes 33 putative functional genes for
T2D, 3 of which were targeted by approved drugs. A further integration of DNA methylation
(n= 1980) and epigenomic annotation data highlight 3 genes (CAMK1D, TP53INP1, and
ATP5G1) with plausible regulatory mechanisms, whereby a genetic variant exerts an effect on
T2D through epigenetic regulation of gene expression. Our study uncovers additional loci,
proposes putative genetic regulatory mechanisms for T2D, and provides evidence of purifying
selection for T2D-associated variants.
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Type 2 diabetes (T2D) is a common disease with a world-wide prevalence that increased rapidly from 4.7% in 1980to 8.5% in 20141. It is primarily caused by insulin resis-
tance (failure of the body's normal response to insulin) and/or
insufﬁcient insulin production by beta cells2. Genetic studies
using linkage analysis and candidate gene approaches have led to
the discovery of an initial set of T2D-associated loci (e.g., PPARG
and TCF7L2)3,4. Over the past decade, genome-wide association
studies (GWAS) with increasing sample sizes have identiﬁed 144
genetic variants (not completely independent) at 129 loci asso-
ciated with T2D5,6.
Despite a large number of variants discovered using GWAS,
the associated variants in total, explains only a small proportion
(~10%) of the heritability of T2D7. This well-known “missing
heritability” problem is likely due to the presence of common
variants (minor allele frequencies or MAF ≥ 0.01) that have small
effects and have not yet been detected and/or rare variants that
are not well tagged by common single nucleotide polymorphisms
(SNPs)7. The contribution of rare variants to genetic variation in
the occurrence of common diseases is under debate8, and a recent
study suggested that the contribution of rare variants to the
heritability of T2D is likely to be limited9. If most T2D-associated
genetic variants are common in the population, continual dis-
coveries of variants with small effects are expected from large-
scale GWAS using the current experimental design. Furthermore,
limited progress has been made in understanding the regulatory
mechanisms of the genetic loci identiﬁed by GWAS. Thus, the
etiology and the genetic basis underlying the development of this
disease remain largely unknown. Recent methodological advances
have provided us with an opportunity to identify functional genes
and their regulatory elements by combining GWAS summary
statistics with data from molecular quantitative trait loci studies
with large sample sizes10,11.
In this study, we perform a meta-analysis of GWAS in a very
large sample of T2D (62,892 cases and 596,424 controls), by
combining 3 GWAS data sets of European ancestry: DIAbetes
Genetics Replication and Meta-analysis (DIAGRAM)5, Genetic
Epidemiology Research on Aging (GERA)12, and the full cohort
release of the UK Biobank (UKB)13. We then integrate the GWAS
meta-analysis results with gene expression and DNA methylation
data to identify genes that might be functionally relevant to T2D
and to infer plausible mechanisms, whereby genetic variants
affect T2D risk through gene regulation by DNA methylation11.
We further estimate the genetic architecture of T2D using whole-
genome estimation approaches. Our study identiﬁes additional
T2D-risk variants, prioritizes functional genes, and proposes
putative genetic regulatory mechanisms for T2D.
Results
Meta-analysis identiﬁes 39 previously unknown loci. We meta-
analyzed 5,053,015 genotyped or imputed autosomal SNPs
(MAF ≥ 0.01) in 62,892 T2D cases and 596,424 controls from the
DIAGRAM (12,171 cases vs. 56,862 controls in stage 1 and
22,669 cases vs. 58,119 controls in stage 2), GERA (6905 cases
and 46,983 controls) and UKB (21,147 cases and 434,460 con-
trols) data sets after quality controls (Supplementary Fig. 1 and
Methods). Summary statistics in DIAGRAM were imputed to the
1000 Genomes Project14 (1KGP) phase 1 using a summary data-
based imputation approach, ImpG15 (Supplementary Note 1),
and we used an inverse-variance method16 to meta-analyze the
imputed DIAGRAM data with the summary data from GWAS
analyses of GERA and UKB (Methods and Fig. 1a). We
demonstrated by linkage disequilibrium (LD) score regression
analysis17,18 that the inﬂation in test statistics due to population
structure was negligible in each data set, and there was no
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Fig. 1 Manhattan plots of common- and rare-variant associations for T2D. a GWAS results for common variants (MAF≥ 0.01) in the meta-analysis. The
39 novel loci are annotated and highlighted in green. b GWAS results of rare variants (0.0001≤MAF < 0.01) in UKB. Four loci with P < 5 × 10−9 are
highlighted in red. The blue lines denote the genome-wide signiﬁcant threshold of P < 5 × 10−8, and the red lines denote a more stringent threshold of
P < 5 × 10−9
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evidence of sample overlap among the 3 data sets (Supplemen-
tary Note 2 and Supplementary Table 1). The mean χ2 statistic
was 1.685. LD score regression analysis of the meta-analysis
summary statistics showed an estimate of SNP-based heritability
h^2SNP
 
on the liability scale of 0.196 (s.e.= 0.011) and an esti-
mate of intercept of 1.049 (s.e.= 0.014), consistent with a model
in which the genomic inﬂation in test statistics is driven
by polygenic effects17. After clumping the SNPs using LD
information from the UKB genotypes (clumping r2 threshold
= 0.01 and window size= 1Mb), there were 139 near-
independent variants at P < 5 × 10−8 (Supplementary Data 1).
All of the loci previously reported by DIAGRAM were still
genome-wide signiﬁcant in our meta-analysis results. The most
signiﬁcant association was at rs7903146 (P= 1.3 × 10−347) at the
known TCF7L2 locus4,19. Among the 139 variants, 39 are not in
LD with the known variants (Fig. 1 and Table 1). The result
remained unchanged when the GERA cohort was imputed to
Haplotype Reference Consortium (HRC) (Supplementary Fig. 2).
We regarded these 39 variants as novel discoveries; more than
half of them passed a more stringent signiﬁcance threshold at
P < 1 × 10−8 (Table 1), a conservative control of genome-wide
false-positive rate (GWFPR) suggested by a recent simulation
study20. The functional relevance of some novel gene loci to the
disease was supported by existing biological or molecular evi-
dence related to insulin and glucose (Supplementary Note 3).
Forest plots showed that the effect directions of the 39 novel loci
were consistent across the 3 GWAS data sets (Supplementary
Fig. 3). Regional association plots showed that some loci have
complicated LD structures, and it is largely unclear which
genes are responsible for the observed SNP-T2D associations
(Supplementary Fig. 4). We also performed gene-based analysis
by GCTA-fastBAT21, and conditional analysis by GCTA-
COJO22, and discovered 4 loci with multiple independent sig-
nals associated with T2D (Supplementary Notes 4–5, Supple-
mentary Fig. 5, and Supplementary Data 2–4). Polygenic-risk
score analysis showed high classiﬁcation accuracy using
SNPs effects estimated from the meta-analysis (Supplementary
Note 6 and Supplementary Table 2). We further applied a
stratiﬁed LD score regression method23 to dissect the SNP-based
heritability into the contributions from SNPs in different func-
tional annotation categories and cell types (Supplementary
Note 7, Supplementary Figs. 6, 7, Supplementary Data 5, and
Supplementary Table 3).
Table 1 Common variants at 39 previously unknown T2D-associated loci
CHR BP SNP A1 A2 MAF OR (95% CI) PGWAS Nearest gene
1 117530507 rs1127655 C T 0.47 1.04 (1.03–1.06) 2.47E−08 PTGFRN
2 121309759 rs12617659 T C 0.15 0.93 (0.91–0.95) 2.83E−11 LOC105373585 (GLI2)
3 46925539 rs11926707 T C 0.37 0.95 (0.94–0.97) 1.69E−08 PTH1R
3 152053250 rs4472028 T C 0.44 1.05 (1.03–1.06) 2.08E−10 MBNL1
4 83584496 rs993380 A G 0.33 1.05 (1.04–1.07) 4.59E−10 SCD5
4 103988899 rs7674212 T G 0.41 0.95 (0.94–0.97) 6.18E−10 SLC9B2
5 112927686 rs10077431 A C 0.21 0.95 (0.94–0.97) 4.76E−08 YTHDC2
6 50816887 rs72892910 T G 0.17 1.07 (1.05–1.09) 6.43E−11 TFAP2B
6 131898208 rs2246012 C T 0.16 1.05 (1.03–1.07) 2.43E−08 ARG1, MED23
7 103418846 rs2299383 T C 0.42 1.04 (1.03–1.06) 1.49E−08 RELN
7 117510621 rs13239186 T C 0.30 1.06 (1.04–1.07) 2.70E−10 CTTNBP2
8 8168987 rs7841082 T C 0.44 0.96 (0.94–0.97) 4.94E−08 SGK223
8 9188762 rs11774915 T C 0.34 1.05 (1.03–1.07) 8.73E−09 LOC157273 (TNKS)
8 10633159 rs10100265 A C 0.39 1.05 (1.03–1.07) 6.29E−10 PINX1
8 19852310 rs17411031 G C 0.26 0.96 (0.94–0.97) 3.04E−08 LPL
8 30863722 rs10087241 G A 0.41 1.05 (1.03–1.07) 2.80E−09 PURG
8 146003567 rs2294120 G A 0.46 0.96 (0.94–0.97) 1.62E−08 ZNF34
9 34025640 rs1758632 C G 0.38 0.95 (0.94–0.97) 1.36E−09 UBAP2
9 96919182 rs10114341 C T 0.44 0.96 (0.95–0.97) 1.15E−08 LOC107987099 (PTPDC1)
10 71469514 rs2616132 A G 0.47 1.05 (1.03–1.06) 6.58E−09 FAM241B
10 75594050 rs2633310 T G 0.44 0.96 (0.94–0.97) 2.38E−08 CAMK2G
10 101976501 rs11591741 C G 0.44 0.95 (0.94–0.97) 1.23E−09 CHUK
12 26463082 rs11048456 C T 0.24 1.05 (1.03–1.07) 2.97E−09 ITPR2
12 71439589 rs7138300 C T 0.44 1.05 (1.03–1.06) 5.65E−10 TSPAN8
12 93978504 rs11107116 T G 0.22 1.05 (1.03–1.07) 3.75E−08 SOCS2
13 51096095 rs963740 T A 0.29 0.95 (0.94–0.97) 2.23E−08 DLEU1
15 63823301 rs982077 A G 0.43 1.05 (1.03–1.06) 2.58E−10 USP3
16 69666683 rs244415 A G 0.41 0.95 (0.94–0.97) 3.88E−09 NFAT5
17 17653411 rs12945601 T C 0.39 1.05 (1.03–1.07) 1.72E−09 RAI1
17 40542501 rs17405722 A G 0.07 1.09 (1.06–1.12) 2.28E−09 STAT3
17 45885756 rs9911983 C T 0.43 0.96 (0.95–0.97) 4.82E−08 OSBPL7
17 56757584 rs302864 A G 0.09 1.07 (1.05–1.10) 2.46E−08 TEX14
17 61687600 rs17631783 T C 0.26 0.95 (0.94–0.97) 3.95E−08 TACO1
19 19407718 rs10401969 C T 0.08 1.10 (1.07–1.13) 4.13E−12 SUGP1
20 22435749 rs6515236 C A 0.25 0.95 (0.93–0.97) 3.34E−08 LOC105372562 (FOXA2)
20 32675727 rs6059662 A G 0.34 0.96 (0.94–0.97) 1.51E−08 EIF2S2
20 45594711 rs6066138 A G 0.28 0.95 (0.94–0.97) 1.93E−09 EYA2
22 30552813 rs16988333 G A 0.09 0.93 (0.90–0.95) 9.17E−09 HORMAD2
22 44377442 rs4823182 G A 0.34 1.05 (1.03–1.07) 3.36E−10 SAMM50
CHR: chromosome, BP: base pair position in build hg19, A1: minor allele, A2: major allele, MAF: minor allele frequency, OR; odds ratio for A1, PGWAS: association p value from the GWAS meta-analysis,
Nearest gene: if the nearest gene (within 1 Mb) is uncharacterized, a nearest characterized gene is shown in a bracket
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Of all the 139 T2D-associated loci identiﬁed in our meta-
analysis, 16 and 25 were signiﬁcant in insulin secretion and
sensitivity GWAS, respectively, from the MAGIC consortium24,25
(see URLs section) after correcting for multiple tests (i.e., 0.05/
139), with only 1 locus showing signiﬁcant associations with both
insulin secretion and sensitivity. The limited number of over-
lapping associations observed might be due to the relatively small
sample sizes in the insulin studies. We further estimated the
genetic correlation (rg) between insulin secretion (or sensitivity)
and T2D by the bivariate LD score regression approach18 using
summary-level data. The estimate of rg between T2D and insulin
secretion was −0.15 (s.e.= 0.10), and that between T2D and
insulin sensitivity was −0.57 (s.e.= 0.10). Gene set enrichment
test also showed that T2D-associated loci were enriched in
“glucose homeostasis” and “insulin secretion” pathways (Supple-
mentary Note 7, Supplementary Fig. 8, and Supplementary
Data 6–7).
Rare variants associated with T2D. Very few rare variants-
associated with T2D have been identiﬁed in previous studies26–28.
We included 10,849,711 rare variants (0.0001 ≤MAF < 0.01) in
the association analysis in UKB and detected 11 rare variants
at P < 5 × 10−8 and 4 of them were at P < 5 × 10−9 (Fig. 1b
and Supplementary Table 4). We focused only on the 4 signals at
P < 5 × 10−9 because a recent study suggested that a P value
threshold of 5 × 10−9 is required to control a GWFPR at 0.05 in
GWAS, including both common and rare variants imputed from
a fully sequenced reference20. Three of the rare variants were
located at loci with signiﬁcant common variant associations.
Variant rs78408340 (odds ratio (OR)= 1.33, P= 4.4 × 10−14) is a
missense variant that encodes a p.Ser539Trp alteration in PAM
and was reported to be associated with decreased insulin release
from pancreatic beta cells27. Variant rs146886108 (OR= 0.72,
P= 4.4 × 10−9), which showed a protective effect against T2D, is
a novel locus and a missense variant that encodes p.Arg187Gln
in ANKH29. Variant rs117229942 (OR= 0.70, P= 4.0 × 10−11) is
an intron variant in TCF7L24. Variant rs527320094 (OR= 2.74,
P= 4.6 × 10−9), located in LOC105378797, is also a novel rare-
variant association, with no other signiﬁcant SNP (either com-
mon or rare) within a ±1Mb window. We did not observe any
substantial difference in association signals for these 4 variants
between the results from BOLT-LMM30 and logistic regression31
considering the difference in sample size (Supplementary
Table 4).
Gene expression and DNA methylation associated with T2D.
Most previous studies have reported the gene in closest physical
proximity to the most signiﬁcant SNP at a GWAS locus.
However, gene regulation can be inﬂuenced by genetic variants
that are physically distal to the genes32. To prioritize genes
identiﬁed through the genome-wide signiﬁcant loci that are
functionally relevant to the disease, we performed a summary
Table 2 Putative functional genes for T2D identiﬁed from the SMR analysis in eQTLGen
probe ID Chr Gene topSNP A1 A2 Freq PGWAS PeQTL PSMR PHEIDI
55879 1 CD101 rs10737727 C A 0.48 1.1E−07 1.2E−116 2.5E−07 9.2E−03
68011 2 CEP68 rs2249105 G A 0.38 4.1E−10 1.3E−190 1.0E−09 2.9E−02
9391 3 EHHADH rs7431357 A G 0.16 2.4E−07 1.6E−39 1.4E−06 1.2E−01
43929 4 RP11-10L12.4 rs223359 T C 0.48 1.2E−07 <1E−300 1.4E−07 3.1E−02
68382 5 ANKH rs1061813 G A 0.46 3.4E−09 1.4E−110 1.3E−08 3.9E−01
62965 5 POC5 rs10515213 G A 0.21 2.1E−06 1.3E−244 2.5E−06 9.4E−04
40809 6 RREB1 rs2714337 T A 0.35 3.9E−10 2.8E−48 1.0E−08 1.6E−03
44795 6 MICB rs2253042 T C 0.33 2.1E−08 <1E−300 2.0E−08 8.8E−04
29725 6 HLA-DQB1 rs1063355 T G 0.43 3.7E−19 1.5E−38 1.6E−13 7.6E−03
12660 6 CENPW rs1591805 G A 0.51 1.6E−09 1.4E−21 3.8E−07 3.2E−02
56635 6 ARG1 rs2246012 C T 0.15 2.4E−08 <1E−300 2.7E−08 9.0E−01
39116 6 MED23 rs3756784 G T 0.19 2.6E−08 6.9E−67 1.3E−07 8.1E−01
16667 8 TP53INP1 rs10097617 C T 0.51 7.5E−08 9.9E−86 2.4E−07 2.5E−01
17817 8 RPL8 rs2958517 G A 0.47 1.5E−06 <1E−300 1.8E−06 7.0E−01
51129 10 CAMK1D rs11257655 T C 0.20 2.0E−17 <1E−300 1.1E−16 2.3E−02
45148 10 CAMK1D rs11257655 T C 0.20 2.0E−17 3.7E−131 1.2E−15 2.6E−02
51050 10 CAMK1D rs11257655 T C 0.20 2.0E−17 <1E−300 1.3E−16 1.5E−02
14584 10 CAMK1D rs11257655 T C 0.20 2.0E−17 <1E−300 1.2E−16 4.2E−03
55828 10 CWF19L1 rs34027394 A G 0.42 5.2E−09 <1E−300 6.4E−09 4.7E−01
54041 10 SNORA12 rs34762508 T C 0.42 5.8E−09 1.3E−16 1.9E−06 9.1E−01
564 10 PLEKHA1 rs11200629 G A 0.48 5.1E−08 5.0E−151 1.1E−07 1.4E−01
44452 10 PLEKHA1 rs7072204 G A 0.48 5.4E−08 1.8E−180 1.1E−07 1.5E−01
54567 11 SSSCA1 rs1194076 A C 0.24 7.6E−07 1.4E−268 9.3E−07 8.5E−01
59012 11 ARAP1 rs9667947 C T 0.15 2.1E−20 2.0E−10 1.5E−07 5.4E−03
64698 12 P2RX4 rs2071271 T C 0.27 3.6E−07 <1E−300 4.5E−07 2.9E−01
14501 12 CAMKK2 rs11065504 C G 0.36 2.0E−06 <1E−300 2.4E−06 4.3E−03
25086 12 CAMKK2 rs11065504 C G 0.36 2.0E−06 <1E−300 2.4E−06 2.2E−03
19328 15 C15orf38 rs7174878 A G 0.26 5.2E−10 2.5E−214 1.0E−09 3.0E−03
55328 15 RCCD1 rs2290202 T G 0.14 2.3E−07 <1E−300 2.9E−07 2.8E−03
28542 17 ANKFY1 rs4790598 G T 0.38 7.1E−08 1.8E−45 4.5E−07 1.1E−02
9982 17 ATP5G1 rs1962412 T C 0.31 5.6E−11 1.1E−120 2.9E−10 2.6E−03
42278 17 ATP5G1 rs318095 T C 0.48 4.0E−12 3.6E−117 3.9E−11 5.2E−02
60420 17 UBE2Z rs15563 A G 0.48 3.4E−12 1.3E−52 2.6E−10 4.7E−03
60551 17 UBE2Z rs962272 A G 0.48 3.8E−12 9.6E−67 1.4E−10 7.4E−02
Columns are probe ID, probe chromosome, gene name, probe position, SNP name, SNP position, effect allele, other allele, frequency of the effect allele in the reference sample, GWAS P value, eQTL
P value, SMR P value and HEIDI P value
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data-based Mendelian randomization (SMR) analysis33 using the
top-associated expression quantitative trait locus (eQTL) as an
instrumental variable to test for association between the expres-
sion level of each gene and T2D (Methods). We used GWAS
summary data from our meta-analysis and eQTL summary
data from the eQTLGen (n= 14,115) and CAGE consortia (n=
2765)34 for the SMR analysis (Methods). We identiﬁed 40 genes
in eQTLGen and 24 genes in CAGE at an experimental-wise
signiﬁcance level (PSMR < 2.7 × 10−6, i.e., 0.05/mSMR, with
mSMR ¼ 18; 602 being the total number of SMR tests in the 2 data
sets) (Supplementary Data 8–9). To ﬁlter out the SMR associa-
tions due to linkage (i.e., 2 causal variants in LD, one affecting
gene expression and the other affecting T2D risk), all the sig-
niﬁcant SMR associations were followed by a HEterogeneity In
Dependent Instruments (HEIDI)33 analysis to test whether there
is heterogeneity in SMR estimates at SNPs in LD with the top-
associated cis-eQTL (Methods). Therefore, genes not rejected by
HEIDI (i.e., no evidence of heterogeneity) were those associated
with T2D through pleiotropy at a shared genetic variant. Of
the genes that passed the SMR test, 27 genes in eQTLGen
and 15 genes in CAGE were not rejected by the HEIDI test
(PHEIDI > 7.8 × 10−4, i.e., 0.05/mSMR, with mSMR ¼ 64 being the
total number of SMR tests in the 2 data sets) (Tables 2–3 and
Supplementary Data 8–9), with 7 genes in common and 33 unique
genes in total. SNPs associated with the expression levels of genes
including EHHADH (rs7431357), SSSCA1 (rs1194076), and
P2RX4 (rs2071271) in eQTLGen were not signiﬁcant in the T2D
meta-analysis, likely due to the lack of power; these SNPs were
expected to be detected in future studies with larger sample sizes.
To identify the regulatory elements associated with T2D risk,
we performed SMR analysis using methylation quantitative trait
locus (mQTL) data from McRae et al.35 (n= 1980) to identify
DNA methylation (DNAm) sites associated with T2D through
pleiotropy at a shared genetic variant. In total, 235 DNAm
sites were associated with T2D, with PSMR < 6.3 × 10−7
mSMR ¼ 78; 961ð Þ and PHEIDI > 1.6 × 10−4 mHEIDI ¼ 323ð Þ (Sup-
plementary Data 10); these DNAm sites were signiﬁcantly enriched
in promoters (fold change= 1.60, Penrichment= 1.6 × 10−7) and
weak enhancers (fold change= 1.74, Penrichment= 1.4 × 10−2)
(Supplementary Note 8 and Supplementary Fig. 9). Identiﬁcation
of DNAm sites and their target genes relies on consistent
association signals across omics levels11. To demonstrate this, we
conducted the SMR analysis to test for associations between the
235 T2D-associated DNAm sites and the 33 T2D-associated
genes and identiﬁed 22 DNAm sites associated with 16 genes in
eQTLGen (Supplementary Data 11) and 21 DNAm sites
associated with 15 genes in CAGE (Supplementary Data 12) at
PSMR < 2.5 × 10−7 mSMR ¼ 202; 609ð Þ and PHEIDI > 2.1 × 10−4
mHEIDI ¼ 235ð Þ. These results can be used to infer plausible
regulatory mechanisms for how genetic variants affect T2D risk
by regulating the expression levels of genes through DNAm
(see below).
SMR associations in multiple T2D-relevant tissues. To replicate
the SMR associations in a wider range of tissues relevant to T2D,
we performed SMR analyses based on cis-eQTL data from
4 tissues in GTEx36 (i.e., adipose subcutaneous tissue, adipose
visceral omentum, liver, and pancreas). We denoted these 4 tis-
sues as GTEx-AALP. Of the 27 putative T2D genes identiﬁed by
SMR and HEIDI using the eQTLGen data, 10 had a cis-eQTL at
PeQTL < 5 × 10−8 in at least one of the 4 GTEx-AALP tissues
(Supplementary Data 13). Note that the decrease in eQTL
detection power is expected given the much smaller sample size of
GTEx-AALP (n= 153–385) compared to that of eQTLGen (n=
14,115), as demonstrated by simulation (Supplementary Note 9
and Supplementary Fig. 10). As a benchmark, 17 of the 27 genes
had a cis-eQTL at PeQTL < 5 × 10−8 in GTEx-blood (n= 369). We
ﬁrst performed the SMR analysis in GTEx-blood and found that
12 of the 17 genes were replicated at PSMR < 2.9 × 10−3 (i.e., 0.05/
17) (Supplementary Data 13), an expected high replication rate
given the simulation result (Supplementary Fig. 10). We then
conducted the SMR analysis in GTEx-AALP. The result showed
that 8 of the 10 genes showed signiﬁcant SMR associations at
PSMR < 1.3 × 10−3 (i.e., 0.05/40) in at least one of the 4 GTEx-
AALP tissues, a replication rate comparable to that found in
GTEx-blood. Among the 8 genes, CWF19L1, for which the cis-
eQTL effects are highly consistent across different tissues, was
signiﬁcant in all the data sets (Supplementary Fig. 11).
The replication analysis described above depends heavily on
the sample sizes of eQTL studies. A less sample-size-dependent
Table 3 Putative functional genes for T2D identiﬁed from the SMR analysis in CAGE
probe ID Chr Gene topSNP A1 A2 Freq PGWAS PeQTL PSMR PHEIDI
ILMN_1754865 1 PABPC4 rs1985076 C T 0.22 2.0E−12 3.0E−23 8.9E−09 4.1E−01
ILMN_1757343 1 PABPC4 rs17513135 T C 0.23 2.7E−13 7.7E−32 6.3E−10 3.1E−01
ILMN_1795464 6 LTA rs2516479 G C 0.40 3.9E−10 9.4E−28 5.9E−08 5.6E−03
ILMN_1712390 6 CUTA rs115196245 C G 0.03 5.1E−10 1.2E−27 6.7E−08 1.1E−02
ILMN_1812281 6 ARG1 rs2246012 C T 0.15 2.4E−08 1.1E−113 5.3E−08 8.6E−01
ILMN_1714108 8 TP53INP1 rs896853 G C 0.48 1.3E−07 2.3E−33 1.3E−06 4.8E−01
ILMN_1711314 10 NUDT5 rs11257655 T C 0.20 2.0E−17 8.0E−36 2.4E−12 2.8E−03
ILMN_1795561 10 CAMK1D rs11257655 T C 0.20 2.0E−17 2.7E−112 2.2E−15 1.6E−01
ILMN_1751561 10 CAMK1D rs11257655 T C 0.20 2.0E−17 8.6E−102 3.3E−15 8.4E−02
ILMN_1906187 10 LOC283070 rs11257655 T C 0.20 2.0E−17 1.9E−101 3.4E−15 6.9E−03
ILMN_1651886 10 CWF19L1 rs34027394 A G 0.42 5.2E−09 3.0E−130 1.4E−08 4.8E−01
ILMN_1662839 10 PLEKHA1 rs11200594 C T 0.52 1.1E−07 1.8E−44 6.2E−07 1.9E−01
ILMN_1727134 12 KLHDC5 rs12578595 T C 0.20 1.9E−11 9.9E−25 1.7E−08 3.3E−03
ILMN_1813846 12 P2RX4 rs2071271 T C 0.27 3.6E−07 2.1E−68 1.1E−06 2.7E−01
ILMN_1743021 12 CAMKK2 rs35898441 T C 0.35 4.1E−07 9.9E−136 7.5E−07 1.3E−02
ILMN_2367638 12 CAMKK2 rs3794207 T C 0.35 6.5E−07 4.0E−132 1.2E−06 2.6E−02
ILMN_2189406 15 C15orf38 rs12594774 A G 0.26 2.7E−10 4.9E−28 3.8E−08 1.1E−02
ILMN_1712430 17 ATP5G1 rs7212779 A G 0.29 1.6E−10 7.7E−26 4.7E−08 1.5E−02
ILMN_1676393 17 ATP5G1 rs12325727 G A 0.52 6.3E−11 1.1E−31 1.3E−08 2.7E−01
Columns are probe ID, probe chromosome, gene name, probe position, SNP name, SNP position, effect allele, other allele, frequency of the effect allele in the reference sample, GWAS P value, eQTL
P value, SMR P value, and HEIDI P value
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approach is to quantify how well the effects of the top associated
cis-eQTLs for all the 27 putative T2D genes estimated in blood
(i.e., the eQTLGen data) correlate with those estimated in the
GTEx tissues, accounting for sampling variation in estimated SNP
effects37. This approach avoids the need to use a stringent P value
threshold to select cis-eQTLs in the GTEx tissues with small
sample sizes. We found that the mean correlation of cis-eQTL
effects between eQTLGen blood and GTEx-AALP was 0.47
(s.e.= 0.16), comparable to and not signiﬁcantly different from
the value of 0.64 (s.e.= 0.16) between eQTLGen and GTEx-
blood. We also found that the estimated SMR effects of 18 genes,
which passed the SMR test and were not rejected by the HEIDI
test in either eQTLGen or GTEx, were highly correlated
(Pearson’s correlation r= 0.80) (Supplementary Fig. 12). Note
that this correlation is not expected to be unity because of
differences in the technology used to measure gene expression
(Illumina gene expression arrays for eQTLGen vs. RNA-seq for
GTEx). We also performed co-localization analyses using
COLOC38, a Bayesian approach to seek evidence of a locus
associated with two traits. We found that most of the genes that
passed the genome-wide signiﬁcant threshold in the SMR test also
had extremely high posterior probabilities of associations with
T2D from the COLOC analysis (Supplementary Fig. 13).
These results support the validity of using eQTL data from
blood for the SMR and HEIDI analysis; using this method, we can
make use of eQTL data from very large samples to increase the
statistical power, consistent with the conclusions of a recent
study37. In addition, tissue-speciﬁc effects that are not detected in
blood will affect the power of the SMR and HEIDI analysis rather
than generating false positive associations.
Putative regulatory mechanisms for 3 T2D genes. Here, we used
the genes CAMK1D, TP53INP1, and ATP5G1 as examples to
hypothesize possible mechanisms of how genetic variants affect
T2D risk by controlling DNAm for gene regulation11. Functional
gene annotation information was acquired from the Roadmap
Epigenomics Mapping Consortium (REMC)39.
The signiﬁcant SMR association of CAMK1D with T2D was
identiﬁed in both eQTL data sets (Tables 2–3 and Supplementary
Data 8–9). The top eQTL, rs11257655, located in the intergenic
region (active enhancer) between CDC123 and CAMK1D, was
also a genome-wide signiﬁcant SNP in our meta-analysis (P=
2.0 × 10−17). It was previously shown that rs11257655 is located
in the binding motif for FOXA1/FOXA2 and that the T allele of
this SNP is a risk allele that increases the expression level of
CAMK1D through allelic-speciﬁc binding of FOXA1 and
FOXA240. Another functional study demonstrated that increasing
the expression of FOXA1 and its subsequent binding to enhancers
was associated with DNA demethylation41. Our analysis was
consistent with previous studies in showing that the T allele of
rs11257655 increases both CAMK1D transcription (β^ ¼ 0:553,
s.e.= 0.014, where β is the allele substitution effect on gene
expression in standard deviation units) and T2D risk (OR=
1.076, s.e.= 0.009) (Supplementary Data 8, 9, and 11). Moreover,
rs11257655 was also the top mQTL (Fig. 2); the T allele of this
SNP is associated with decreased methylation at the site
cg03575602 in the promoter region of CAMK1D, suggesting that
the T allele of rs11257655 up-regulates the transcription of
CAMK1D by reducing the methylation level at cg03575602.
Leveraging all the information above, we proposed the following
model of the genetic mechanism at CAMK1D for T2D risk
(Fig. 3). In the presence of the T allele at rs11257655, FOXA1/
FOXA2 and other transcription factors bind to the enhancer
region and form a protein complex that leads to a decrease in the
DNAm level of the promoter region of CAMK1D and recruits the
RNA polymerase to the promoter, resulting in an increase in the
expression of CAMK1D (Fig. 3). A recent study showed that the T
risk allele is correlated with reduced DNAm and increased
chromatin accessibility across multiple islet samples42 and that it
is associated with disrupted beta cell function43. Our inference
highlights the role of promote–enhancer interaction in gene
regulation, analytically indicated by the integrative analysis using
the SMR and HEIDI approaches.
The second example is TP53INP1, the expression level of which
was positively associated with T2D as indicated by the SMR
analysis (Table 2 and Supplementary Data 8). This was supported
by previous ﬁndings that the protein encoded by TP53INP1
regulated the TCF7L2-p53-p53INP1 pathway in such a way as to
induce apoptosis and that the survival of pancreatic beta cells was
associated with the level of expression of TP53INP144. TP53INP1
was mapped as the target gene for three DNAm sites
(cg13393036, cg09323728, and cg23172400) by SMR (Fig. 4).
All 3 DNAm sites were located in the promoter region of
TP53INP1 and had positive effects on the expression level of
TP53INP1 and on T2D risk (Supplementary Data 8, 10, and 11).
Based on these results, we proposed the following hypothesis for
the regulatory mechanism (Fig. 5). When the DNAm level of the
promoter region is low, expression of TP53INP1 is suppressed
due to the binding of repressor(s) to the promoter. When the
DNAm level of the promoter region is high, the binding of
repressor(s) is disrupted, allowing the binding of transcription
factors that recruit RNA polymerase and resulting in up-
regulation of gene expression. Increased expression of this gene
has been shown to increase T2D risk by decreasing the survival
rate of pancreatic beta cells through a TCF7L2-p53-p53INP1-
dependent pathway.
The third example involves 2 proximal genes, ATP5G1 and
UBE2Z, the expression levels of which were signiﬁcantly
associated with T2D according to the SMR analysis (Table 2 and
Supplementary Data 8). A methylation probe (cg16584676)
located in the promoter region of UBE2Z was associated with
the expression levels of both ATP5G1 and UBE2Z (Supplemen-
tary Fig. 14a), suggesting that these two genes are co-regulated by
a genetic variant through DNAm. The effect of cg16584676 on
gene expression was negative (Supplementary Data 11 and 12),
implying the following plausible mechanism. A genetic variant
near ATP5G1 exerts an effect on T2D by increasing the DNAm
levels of the promoters for ATP5G1 and UBE2Z; this decreases
the binding afﬁnity of the transcription factors that recruit RNA
polymerase, resulting in down-regulation of gene expression and
ultimately leading to an increase in T2D risk (Supplementary
Fig. 14b). ATP5G1 has been shown to encode a subunit of
mitochondrial ATP synthase, and UBE2Z is a ubiquitin-
conjugating enzyme. Insulin receptors could be degraded by
SOCS proteins during ubiquitin-proteasomal degradation, and
ATP5G1 and UBE2Z are likely to be involved in this pathway45.
The function of insulin receptors is to regulate glucose home-
ostasis through the action of insulin and other tyrosine kinases,
and dysfunction of these receptors leads to insulin resistance and
increases T2D risk.
The 3 examples above provide hypotheses for how genetic
variants may affect T2D risk through regulatory pathways and
demonstrate the power of integrative analysis of omics data for
this purpose. These examples describe putative candidates that
could be prioritized in future functional studies.
Potential drug targets. In the SMR analysis described above, we
identiﬁed 33 putative T2D genes. We matched these genes in the
DrugBank database (see URLs section) and found that 3 genes
(ARG1, LTA, and P2RX4) are the targets of several approved
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drugs (drugs that have been approved in at least one jurisdiction).
ARG1 (UniProt ID: P05089), whose expression level was nega-
tively associated with T2D risk, is targeted by three approved
drugs: ornithine (DrugBank ID: DB00129), urea (DrugBank ID:
DB03904), and manganese (DrugBank ID: DB06757), but the
pharmacological mechanism of action of these drugs remains
unknown. Arginase (ARG1 is an isoform of arginase in liver) is a
manganese-containing enzyme that catalyzes the hydrolysis of
arginine to ornithine and urea. Arginase in vascular tissue might
be a potential therapeutic target for the treatment of vascular
dysfunction in diabetes46. Metformin, an oral antidiabetic drug
that is used in the treatment of diabetes, was reported to increase
ARG1 expression in a murine macrophage cell line47, consistent
with our SMR result that increased expression of ARG1 was
associated with decreased T2D risk (Supplementary Data 8).
There was also evidence for an interaction between ARG1 and
metformin (Comparative Toxicogenomics Database, see URLs
section). The likely mechanism is that metformin activates AMP-
activated protein kinase (AMPK), resulting in increased expres-
sion of ARG148, again consistent with our SMR result. LTA
(UniProt ID: P08637), whose expression level was negatively
associated with T2D risk, is targeted by the approved drug eta-
nercept (DrugBank ID: DB00005) for rheumatoid arthritis (RA)
treatment. P2RX4 (UniProt ID: Q99571), the expression level of
which was positively associated with T2D risk, is targeted by
eslicarbazepine acetate (DrugBank ID: DB09119; antagonist for
P2RX4). Eslicarbazepine acetate is an anticonvulsant that inhibits
repeated neuronal ﬁring and stabilizes the inactivated state of
voltage-gated sodium channels; its pharmacological action makes
it useful as an adjunctive therapy for partial-onset seizures49.
Antagonists of P2RX4 inhibit high glucose and are useful in the
treatment of diabetic nephropathy50. We also explored whether
any of these three genes have potential adverse effects by checking
the associations of the lead variants at the three loci with lipid-
18
–l
og
10
(P
 G
W
A
S
 o
r 
S
M
R
)
–l
og
10
(P
 e
Q
T
L)
–l
og
10
(P
 m
Q
T
L)
cg0
35
75
60
2
cg1
68
94
85
5
cg1
45
37
54
9
cg1
07
04
39
5
cg2
61
69
08
1
51
12
9 (C
AMK
1D)
45
14
8 (C
AMK
1D)
51
05
0 (C
AMK
1D)
14
58
4 (C
AMK
1D)
rs1
12
57
65
5
14
9
4
0
51129 (CAMK1D)
cg03575602 (NUDT5, CDC123, CAMK1D, LOC283070)
cg16894855 (NUDT5, CDC123, CAMK1D, LOC283070)
458
305
153
0
36
24
12
0
0
ESC
iPSC
ES-deriv
Blood & T-cell
HSC & B-cell
Epithelial
Brain
Muscle
Heart
Digestive
Other
ENCODE
11.87 12.11 12.34 12.58
Chromosome 10 Mb
12.82 13.05
PROSER2–AS1
UPF2
DHTKD1
MIR548AK
SEC61A2
NUDT5
CDC123
CAMK1D
MIR4480
MIR4481
TssA
PromU
PromD1
PromD2
Tx5′
Tx3′
TxWk
TxReg
TxEnh5′
TxEnh3′
TxEnhW
Quies
EnhA1
EnhA2
EnhAF
EnhW1
EnhW2
EnhAc
DNase
ZNF/Rpts
Het
PromP
PromBiv
ReprPC
Tx
Mesenchymal
30
20
10
*
pMSMR = 6.3e–07
pESMR = 2.7e–06
Fig. 2 Prioritizing genes and regulatory elements at the CAMK1D locus for T2D. The results of the SMR analysis that integrates data from GWAS, eQTL, and
mQTL studies are shown. The top plot shows −log10(P value) of SNPs from the GWAS meta-analysis for T2D. Red diamonds and blue circles represent
−log10(P value) from the SMR tests for associations of gene expression and DNAm probes with T2D, respectively. Solid diamonds and circles represent the
probes not rejected by the HEIDI test. The yellow star denotes the top cis-eQTL SNP rs11257655. The second plot shows −log10(P value) of the SNP
association for gene expression probe 51129 (tagging CAMK1D). The third plot shows −log10(P value) of the SNP association with DNAm probes
cg03575602 and cg16894855 from the mQTL study. The bottom plot shows 25 chromatin state annotations (indicated by colors) of 127 samples from
Roadmap Epigenomics Mapping Consortium (REMC) for different primary cells and tissue types (rows)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04951-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2941 | DOI: 10.1038/s41467-018-04951-w | www.nature.com/naturecommunications 7
and insulin-related traits from previous studies (Supplementary
Note 10 and Supplementary Data 14). We further found two
additional genes that are targeted by an approved veterinary drug
and a nutraceutical drug, respectively (Supplementary Note 10).
Natural selection of T2D-associated variants. We performed an
LD- and MAF-stratiﬁed GREML analysis51 (Methods) in a subset
of unrelated individuals in UKB (n= 15,767 cases and 104,233
controls) to estimate the variance explained by SNPs in different
MAF ranges (m= 18,138,214 in total). We partitioned the SNPs
into 7 MAF bins with high- and low-LD bins within each MAF
bin to avoid MAF- and/or LD-mediated bias in h^2SNP (Methods).
The h^2SNP was 33.2% (s.e.= 2.1%) on the liability scale (Supple-
mentary Table 5). Under an evolutionary neutral model and a
constant population size52, the explained variance is uniformly
distributed as a function of MAF, which means that the variance
explained by variants with MAF ≤ 0.1 equals that explained by
variants with MAF > 0.4. However, in our results, the MAF bin
containing low-MAF and rare variants (MAF ≤ 0.1) showed a
larger estimate than any other MAF bin (Fig. 6a and Supple-
mentary Table 5), consistent with a model of negative (purifying)
selection or population expansion53. To further distinguish
between the two models (negative selection vs. population
expansion), we performed an additional analysis using a recently
developed method, BayesS54 (implemented in GCTB, see URLs
section) to estimate the relationship between variance in effect
size and MAF (Methods). The method also allowed us to estimate
h^2SNP and polygenicity (π) on each chromosome. The results
(Fig. 6b) showed that the h^2SNP of each chromosome was highly
correlated with its length (Pearson’s correlation r= 0.92). The
mean estimate of π, i.e., the proportion of SNPs with non-zero
effects, was 1.75% across all chromosomes (Fig. 6c and
Supplementary Table 6), suggesting a high degree of polygenicity
for T2D. The sum of per-chromosome h^2SNP from BayesS was
31.9% (s.e.= 4.1%) on the liability scale, slightly higher than that
based on HapMap3 SNPs from a Haseman-Elston regression
analysis (28.7%, s.e.= 1.1%) using a full set of unrelated UKB
individuals (n= 348,580) or from an LD score regression analysis
(22.6%, s.e.= 1.2%) using all the UKB individuals (n= 455,607)
(Supplementary Table 7). The variance in effect size was sig-
niﬁcantly negatively correlated with MAF (S^ = −0.53, s.e.=
0.09), consistent with a model of negative selection on deleterious
rare alleles (Fig. 6d) and inconsistent with a recent study9 con-
cluding that T2D-associated loci have not been under natural
selection. Our conclusion regarding negative selection is also
consistent with the observation that the minor alleles of 9 of the
11 rare variants at P<5 ´ 108 were T2D risk alleles (Supple-
mentary Table 4). The signal of negative selection implies that a
large number of rare variants are expected to be discovered in
future GWAS in which appropriate genotyping strategies are
used.
Discussion
In this study, we sought to identify novel genetic loci associated
with T2D by a meta-analysis of GWAS with a very large sample
size and to infer plausible genetic regulation mechanisms at
known and novel loci by an integrative analysis of GWAS and
omics data. We identiﬁed 139 near-independent common var-
iants P<5 ´ 108ð Þ and 4 rare variants P<5 ´ 109ð Þ for T2D in
the meta-analysis. Of the 139 common loci, 39 were novel
compared with the results of all 49 previous T2D GWAS from the
GWAS Catalog (see URLs section)55, including the 2 recent
studies by DIAGRAM56 and Zhao et al.57. We did not detect
evidence for sex or age heterogeneity in UKB (Supplementary
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Note 11, Supplementary Fig. 14, and Supplementary Table 8). By
integrating omics data, we have inferred the genetic mechanisms
for the 3 genes CAMK1D, TP53INP1, and ATP5G1; the
inferred mechanisms suggest that enhancer-promoter interac-
tions with DNA methylation play an important role in
mediating the effects of genetic variants on T2D risk. These
ﬁndings provide deeper insight into the etiology of T2D and
suggest candidate genes for functional studies in the future.
Furthermore, our estimation of genetic architecture suggests that
T2D is a polygenic trait for which both rare and common variants
contribute to the genetic variation and indicates that rarer
variants tend to have larger effects on T2D risk (Fig. 6c and
Supplementary Table 4). Assuming that most new mutations
are deleterious for ﬁtness, our result is consistent with a model
in which mutations that have larger effects on T2D (and thereby
on ﬁtness through pleiotropy) are more likely to be maintained
at low frequencies in the population by negative (purifying)
selection.
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This study has a number of limitations. First, the SNP-T2D
associations identiﬁed by the meta-analysis might be biased by
misdiagnosis of T1D (type 1 diabetes) and latent autoimmune
diabetes in adults58. Previous studies found that biases in SNP-
T2D associations due to misdiagnosis are likely to be very
modest5,56. We showed by 2 additional analyses based on known
T1D loci that most of the novel SNP-T2D associations identiﬁed
in this study are unlikely to be driven by misdiagnosed T1D cases
(Supplementary Note 12 and Supplementary Data 15). Second,
some of the T2D-associated SNPs might confer T2D risk through
mediators such as obesity or dyslipidemia. To explore this pos-
sibility, we performed a summary data-based conditional analysis
of the 139 T2D-associated SNPs conditioning on body mass
index (BMI) or dyslipidemia by GCTA-mtCOJO59 using GWAS
data for these 2 traits from UKB. It appeared that the effect sizes
of most T2D-associated SNPs, with the exception of a few outliers
(e.g., FTO,MC4R, POCS, and TFAP2B), were not affected by BMI
or dyslipidemia (Supplementary Fig. 16). These outliers were
among those showing the strongest associations with BMI60.
Third, among the 39 novel loci, there was only 1 locus (ARG1/
MED23, Supplementary Fig. 17) at which the association between
gene expression and T2D risk was signiﬁcant in SMR and not
rejected by HEIDI (Tables 2–3). This is because the power of the
SMR test depends primarily on the SNP effect from GWAS10,
which is small for the novel loci. Fourth, the sample sizes of eQTL
data from the disease relevant tissues were relatively small. We
used the eQTL data from blood to take advantage of the large
sample sizes. This maximized the power for detecting genes for
which the eQTL effects are consistent across tissues (Supple-
mentary Fig. 10) but might have missed genes for which the
eQTL effects are speciﬁc to the T2D-relevant tissues. Moreover,
the pancreatic islets constitute only 1–2% of the whole pancreas
volume61 and previous studies revealed islet-speciﬁc gene activity
for T2D62,63. Therefore, in our SMR analysis using GTEx-
pancreas data, genes with islet-speciﬁc transcription or eQTL
effects could be missed. Finally, we employed the SMR and
HEIDI methods to map CpG sites to their target genes and to
identify the CpG sites associated with T2D because of pleiotropy.
The SMR approach uses genome-wide signiﬁcant mQTL as an
instrumental variable for each CpG site, which requires a large
sample size for the mQTL discovery. In this study, we used
mQTL data based on Illumina HumanMethylation450 arrays
because of the relatively large sample size (n= 1980). Unfortu-
nately, we did not have access to mQTL data from whole-genome
bisulﬁte sequencing (WGBS) in a large sample. Nevertheless, it is
noteworthy that there are three T2D-associated variants at the
CAMK1D/CDC123, ADCY5, and KLHDC5 loci that show hypo-
methylation and allelic imbalance as identiﬁed by Thurner et al.42
using WGBS data (n= 10), all of which were genome-wide sig-
niﬁcant in our mQTL-based SMR analysis. In addition, a previous
study showed that T2D-associated loci were enriched in islet
stretch enhancers63, ~54.1% of which were tagged by at least one
of the DNAm probe in the 450 K array (annotation data from
ref. 64). Despite these limitations, our study highlights the beneﬁts
of integrating multiple omics data to identify functional genes
and putative regulatory mechanisms driven by local genetic var-
iation. Future applications of integrative omics data analyses are
expected to improve our understanding of the biological
mechanisms underlying T2D and other common diseases.
Methods
Summary statistics of DIAGRAM, GERA, and UKB. The data used in this study
were derived from 659,316 individuals of European ancestry and a small cohort
from Pakistan, and were obtained from three data sets: DIAbetes Genetics Repli-
cation And Meta-analysis (DIAGRAM)5, Genetic Epidemiology Research on Adult
Health and Aging (GERA)12 and UKB13.
DIAGRAM: The DIAGRAM data were obtained from publicly available
databases (see URLs section) and included 2 stages of summary statistics. In stage
1, there were 12,171 cases and 56,862 controls from 12 GWAS cohorts of European
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Transcription
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Fig. 5 Hypothesized regulatory mechanism at the TP53INP1 locus for T2D. When the promoter region is highly methylated, which prevents binding of
repressor protein (red rounded rectangle) to the promoter region, RNA polymerase II (green ellipsoid), transcription factor protein (orange ellipsoid) and
mediator proteins (gray circles) will form a transcription initiation complex that increases the transcription. However, when the methylation level of the
promoter region is low, repressor protein can more efﬁciently bind to the promoter, blocking the binding of the transcription initiation complex to the
promoter, which decreases the transcription of TP53INP1
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descent, and the genotype data were imputed to the HapMap2 Project65 (~2.5
million SNPs after quality control). In stage 2, there were 22,669 cases and 58,119
controls genotyped on Metabochips (~137,900 SNPs), including 1178 cases and
2472 controls of Pakistani descent. There was limited evidence of genetic
heterogeneity between individuals of European and those of Pakistani descent for
T2D5. The sample prevalence was 23.3% (17.6% in stage 1 and 28.1% in stage 2).
We imputed the stage 1 summary statistics by ImpG15 and combined the imputed
data with stage 2 summary statistics (Supplementary Note 1).
GERA: There were 6905 cases and 46,983 controls in GERA, and the sample
prevalence was 12.4%. We cleaned the GERA genotype data using standard quality
control (QC) ﬁlters (excluding SNPs with missing rate ≥ 0.02, Hardy-Weinberg
equilibrium test P value ≤ 1 × 10–6 or minor allele count ≤ 1 and removing
individuals with missing rate ≥ 0.02) and imputed the genotype data to the 1000
Genomes Projects (1KGP) reference panels14 using IMPUTE266. We used GCTA67
(see URLs section) to compute the genetic relationship matrix (GRM) of all the
individuals based on a subset of imputed SNPs (HapMap3 SNPs with MAF ≥ 0.01
and imputation info score ≥ 0.3), removed the related individuals at a genetic
relatedness threshold of 0.05, and retained 53,888 individuals (6905 cases and
46,983 controls) for further analysis. We computed the ﬁrst 20 principal
components (PCs) from the GRM. The summary statistics in GERA were obtained
from a GWAS analysis using PLINK231 with sex, age, and the ﬁrst 20 PCs ﬁtted as
covariates. To examine the inﬂuence of imputation panel on the meta-analysis
result, we further imputed GERA to the HRC68 using the Sanger imputation service
(see URLs section).
UKB: Genotype data from UKB were cleaned and imputed to HRC by the UKB
team13. There were 21,147 cases and 434,460 controls, and the sample prevalence
was 5.5%. We identiﬁed a European subset of UKB participants (n= 456,426) by
projecting the UKB participants onto the 1KGP PCs. Genotype probabilities
were converted to hard-call genotypes using PLINK231 (hard-call 0.1), and we
excluded SNPs with minor allele count < 5, Hardy-Weinberg equilibrium test
P value < 1 × 10–6, missing genotype rate > 0.05, or imputation info score < 0.3.
The UKB phenotype was acquired from self-report, ICD10 main diagnoses and
ICD10 secondary diagnoses (ﬁeld IDs: 20002, 41202, and 41204). The GWAS
analysis in UKB was conducted in BOLT-LMM30 with sex and age ﬁtted as
covariates. In the BOLT-LMM analysis, we used 711,933 SNPs acquired by
LD pruning (r2 < 0.9) from Hapmap3 SNPs to control for relatedness,
population stratiﬁcation and polygenic effects. We transformed the effect size from
BOLT-LMM on the observed 0–1 scale to the OR using LMOR69.
Inverse variance based meta-analysis. Before conducting the meta-analysis, we
performed several analyses in which we examined genetic heterogeneity and
sample overlap among data sets (Supplementary Note 2). We performed a 2-stage
meta-analysis. The ﬁrst stage combined DIAGRAM stage 1 (GWAS chip) data with
GERA and UKB. The second stage combined DIAGRAM stage 1 and 2 (GWAS
chip and metabolism chip) with GERA and UKB. We extracted the SNPs common
to the 3 data sets (5,526,193 SNPs in stage 1 and 5,053,015 million SNPs in stage 2)
and performed the meta-analyses using an inverse-variance based method in
METAL16. The stage 2 meta-analysis data were used in the follow-up analyses.
Summary-data-based Mendelian randomization analysis. We performed SMR
and HEIDI analyses10 to identify genes whose expression levels were associated
with a trait due to pleiotropy using summary statistics from GWAS and eQTL/
mQTL studies. We ﬁrst performed the SMR analysis to test for association between
the expression level of each gene and the disease using the top associated cis-eQTL
of the gene as an instrumental variable (in a Mendelian randomization analysis
framework). There are at least two models consistent with an observed SMR
association, i.e., pleiotropy (a genetic variant having effects on both trait and gene
expression) and linkage (2 genetic variants in LD, one affecting the trait and
another affecting gene expression). The HEIDI test10 uses multiple SNPs in a cis-
eQTL region to distinguish pleiotropy from linkage by testing whether there is
heterogeneity in SMR effects estimated at different SNPs in LD with the top
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associated cis-eQTL. We used the SMR and HEIDI methods to test for pleiotropic
associations between gene expression and T2D, between DNAm and T2D, and
between T2D-associated gene expression and T2D-associted DNAm. In the SMR
analysis, we used eQTL summary data from the eQTLGen Consortium (n= 14,115
in whole blood), the CAGE (n= 2765 in peripheral blood)34 and the GTEx v7
release (n= 385 in adipose subcutaneous tissue, n= 313 in adipose visceral
omentum, n= 153 in liver, n= 220 in pancreas and n= 369 from whole blood)36.
In CAGE and eQTLGen, gene expression levels were measured using Illumina gene
expression arrays; in GTEx, gene expression levels were measured by RNA-seq.
The SNP genotypes in all cohorts were imputed to 1KGP. The cis-eQTL within 2
Mb of the gene expression probes with PeQTL < 5 × 10−8 were selected as the
instrumental variables in the SMR test. The mQTL summary data were obtained
from genetic analyses of DNA methylation measured on Illumina HumanMethy-
lation450 arrays (n= 1980 in peripheral blood)35. We used mQTL data generated
by the 450 K methylation arrays rather than whole-genome bisulﬁte sequencing
(WGBS) because WGBS-based mQTL data of large sample size (at least 100 s) are
not available yet. We demonstrated the statistical power of SMR test in our study
by simulation under a pleiotropy model (Supplementary Note 9 and Supplemen-
tary Fig. 10).
Estimating the genetic architecture for T2D. The MAF- and LD-stratiﬁed
GREML (GREML-LDMS) is a method for estimating SNP-based heritability that is
robust to model misspeciﬁcation51,70. For ease of computation, we limited the
analysis to a subset of unrelated UKB individuals (15,767 cases and 104,233 con-
trols); in this subset, we kept all 15,767 cases among the unrelated individuals to
maximize the sample size of cases and randomly selected 104,233 individuals from
332,813 unrelated controls. We ﬁrst estimated the segment-based LD score, stra-
tiﬁed ~18 million SNPs into 2 groups based on the segment-based LD scores (high
vs. low LD groups separated by the median), and then stratiﬁed the SNPs in each
LD group into 7 MAF bins (10−4 to 10−3, 10−3 to 10−2, 10−2 to 10−1, 0.1–0.2,
0.2–0.3, 0.3–0.4, and 0.4–0.5). We computed the GRMs using the stratiﬁed SNPs
and performed GREML analysis ﬁtting 14 GRMs (with sex, age, and the ﬁrst 10
PCs ﬁtted as covariates) in one model to estimate the SNP-based heritability in
each MAF bin. We used 10% as the population prevalence to convert the estimate
to that on the liability scale.
We used GCTB-BayesS54 to estimate the joint distribution of SNP effect size
and allele frequency. This analysis is based on 348,580 unrelated individuals
(15,767 cases and 332,813 controls) and HapMap3 SNPs (~1.23 million) with sex,
age, and the ﬁrst 10 PCs ﬁtted as covariates. Each SNP effect has a mixture prior of
a normal distribution and a point mass at zero, with an unknown mixing
probability, π, representing the degree of polygenicity. The variance in effect size is
modeled to be dependent on MAF through a parameter S. Under an evolutionarily
neutral model, SNP effect sizes are independent of MAF, i.e., S= 0. A negative
(positive) value of S indicates that variants with lower MAF are prone to having
larger (smaller) effects, consistent with a model of negative (positive) selection. A
Markov-chain Monte Carlo (MCMC) algorithm was used to draw posterior
samples for statistical inference. The posterior mean was used as the point estimate,
and the posterior standard error was approximated by the standard deviation of the
MCMC samples. We conducted the analysis chromosome-wise for ease of
computation.
URLs. For MAGIC consortium, see https://www.magicinvestigators.org/.
For DrugBank, see https://www.drugbank.ca/. For DrugBank documentation, see
https://www.drugbank.ca/documentation. For GWAS catalog, see http://www.ebi.
ac.uk/gwas/. For DIAGRAM summary data, see http://www.diagram-consortium.
org/. For Sanger imputation service, see https://imputation.sanger.ac.uk/. For
GCTA, see http://cnsgenomics.com/software/gcta/. For GCTB, see http://
cnsgenomics.com/software/gctb/.
Data availability. Summary statistics from the meta-analysis are available at http://
cnsgenomics.com/data.html.
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